Today's Edition
ABU DHABI (ALETIHAD)
Mansoor Ibrahim Al Mansoori, Chairman of the Department of Health – Abu Dhabi (DoH), has stated that the launch of Neuralink’s UAE-PRIME clinical trial in Abu Dhabi - the first international site outside North America - marks a powerful moment for the future of health.
He made the statements following the recent announcement by Neuralink regarding the launch of their first clinical trial in the Middle East, UAE-PRIME, at Cleveland Clinic Abu Dhabi in partnership with DoH.
The UAE-PRIME trial explores how individuals with motor and speech impairment can use thought to control devices and communicate.
"In collaboration with Cleveland Clinic Abu Dhabi, we are proud to enable the safe and responsible advancement of brain-computer interface technology, offering renewed hope to individuals living with severe neurological conditions," Al Mansoori said.
He noted that this partnership exemplifies "Abu Dhabi’s commitment to innovation in health and life sciences - driving the acceleration of breakthrough technologies that are purposefully tested, ethically governed, and made accessible to patients around the world."
